Business
Medicenna Announces Completion of Enrolment in MDNA55 Phase 2b Recurrent Glioblastoma Clinical Study
Medicenna Announces Completion of Enrolment in MDNA55 Phase 2b Recurrent Glioblastoma Clin...
About this update from Medicenna Therapeutics Corp.
[{"type":"text","content":"\n\n\n\nMedicenna Announces Completion of Enrolment in MDNA55 Phase 2b Recurrent Glioblastoma Clinical Study\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n.prntac{\nTEXT-ALIGN: CENTER\n}\n\n\n\n\n\n\n\nCanada NewsWire\nTORONTO and HOUSTON, April 30, 2019\n\n\n\nInterim Top-Line Results to be Announced in June, 2019\n TORONTO and HOUSTON, April 30, 2019 /CNW/ - Medicenna Therapeutics Corp. (\"Medicenna\" or the \"Company\") (TSX: MDNA; OTCQB: MDNAF), a clinical stage immuno-oncology company, is pleased to announce that it has completed enrolment in the Phase 2b clinical study of MDNA55 for the treatment of recurrent glioblastoma (rGBM), the most common and uniformly fatal form of brain cancer.\n\"The completion of patient enrolment with our flagship clinical asset is a significant milestone for Medicenna and we look forward to reporting interim top-line data from this trial in June 2019.\" said Dr. Fahar Merchant, Chairman, President and CEO, \"Glioblastoma is a devastating disease and it is particularly aggressive in patients overexpressing the IL4 receptor (IL4R), a biomarker that is specifically targeted by MDNA55. The interim results we presented in February 2019 demonstrated that a single low dose treatment with MDNA55 was able to extend survival by 2-fold to 15.2 months in rGBM patients expressing the IL4R when compared to expected survival of 6 to 8 months. We would like to thank our shareholders for their patience, the Cancer Prevention and Research Institute of Texas (CPRIT) for a generous grant, investigators, clinical sites, patients and their families for their continued support to bring MDNA55 to patients who need it the most.\"\nThe Company is now evaluating data from 25 patients with rGBM treated at the high dose and assessing the impact of IL4R expression on survival outcomes as well as tumor response. Interim top-line results for all patients will be announced this quarter. To date MDNA55 has been used to treat more than 130 patients in multiple clinical trials, including more than 110 patients with rGBM, building a significant safety profile, evidence of anti-tumo...